Rifabutin
ATC Code
J04AB04
Rifabutin
Definition
A semisynthetic ansamycin antibiotic with potent antimycobacterial properties. Rifabutin inhibits bacterial DNA-dependent RNA polymerase, thereby suppressing the initiation of RNA formation and leading to inhibition of RNA synthesis and transcription. (NCI04)
Also known as LM-427, Mycobutin, RIFABUTIN — per NCIT
Also identified as
- ATC J04AB04 per RXNORM
- NCIT NCIT:C1408 per NCIT
- SCTID 108684009 per RXNORM
- SCTID 386893001 per RXNORM
- UNII 1W306TDA6S per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Mycobacterium avium complex disease | may prevent | MEDRT · Public domain (U.S. Government work) |
| Pulmonary tuberculosis | may prevent | MEDRT · Public domain (U.S. Government work) |
| Mycobacterium avium complex disease | may treat | MEDRT · Public domain (U.S. Government work) |
| Pulmonary tuberculosis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Lungs | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Respiratory system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.